September 23, 2021 -- InvestorsHub NewsWire --
NetworkNewsWire
Editorial Coverage: Navigating today’s healthcare systems can
be overwhelming. Outrageous costs combined with complex processes
have created a healthcare system renowned for overpriced
inefficiency; PolicyAdvice reported that in 2018, the global
healthcare market topped $8.45
trillion, which represents about 10% of GDP in developed
countries. Clearly the industry is desperate for solutions that
both improve health outcomes and lower costs. As with many sectors,
those solutions are found in technology. Savvy companies operating
in the space are recognizing the power healthcare technology
(healthtech) and medical technology (medtech) wield in offering
next-generation innovation that answers the call to both flatten
the healthcare spending curve and provide patients and providers
with treatments that work. Already in place prior to COVID-19, the
healthcare tech trend has only accelerated adoption of
self-diagnostic and remote solutions that have been welcomed by
all. Some companies, such as Nemaura Medical Inc.
(NASDAQ:
NMRD) (Profile), are focusing on specific areas of
unmet medical need, including diabetes and obesity. Nemaura is
joined by other astute companies, such as WW
International Inc. (NASDAQ: WW), Teladoc
Health Inc. (NYSE: TDOC), DexCom Inc.
(NASDAQ: DXCM) and DarioHealth
Corp. (NASDAQ: DRIO), who are also recognized leaders
in these sectors as they work to provide effective, cost-sensitive
solutions.
- UNC study reports only 12% of participants attain optimal
metabolic health, resulting in increased risk for diabetes, heart
disease and stroke.
- Nemaura Medical’s proprietary BEAT(R) diabetes platform offers
affordable innovation, effective treatment.
- After soft launch, Nemaura inks deals for 200,000 units with
rolling forecast of 2 million sensors over next two years.
- When partnered with predictive technologies such as AI and
machine learning, the future for NMRD platform appears to be vast
and diverse.
Click here to view the custom infographic of
the Nemaura
Medical Inc. editorial.
Distinctively Different from the Rest
The importance of metabolic health on the quality of life cannot
be overestimated. Many experts in the field point to five health
markers — medicine-free readings of blood glucose,
triglycerides, cholesterol, blood pressure and waist circumference
— as key indicators to watch and measure. A
seven-year study by University of North Carolina researchers
reported that only 12% of Americans achieve optimal metabolic
health, with poor metabolic health often increasing the risk for
diabetes, heart disease, stroke and associated comorbidities. The
report noted that patients struggling with obesity posted the
poorest results, with only 0.5% of individuals in this group
achieving optimal metabolic health.
Unfortunately, the rise in obesity, defined as a body mass index
over 30, is fueling an upward trend in diagnoses of diabetes and
prediabetes, which are characterized and defined by poor glucose
control. Often preventable, diabetes and its increasing prevalence
is a cause for concern. The National Diabetes Report indicates
that 10.5% of all
Americans — and 13% of adults — have the disease,
with an incredible 34.5% of Americans identified as
prediabetic.
Those numbers are no less alarming worldwide, with 463 million
people diagnosed with diabetes globally. Data from the World Health
Organization indicates that 3.4 million people worldwide die from
diabetes each year, although the actual number of deaths attributed
to the disease may be difficult to ascertain because diabetics
often suffer from myriad health problems including damaged heart,
blood vessels, kidneys, eyes and nerves.
For the past decade, Nemaura Medical Inc. (NASDAQ: NMRD)
has focused on developing the world’s first daily-wear, noninvasive
glucose sensor and integrated healthcare app. The company’s BEAT(R)
diabetes platform, including its proprietary sugarBEAT(R) CGM and
proBEAT(TM) offerings, combines noninvasive glucose data processed
using artificial intelligence (“AI”) and a digital healthcare
subscription service.
These solutions are distinctively different from others in both
form and function. The platform is designed to use an integrated
approach that supports and enables individuals to succeed in their
efforts to lose weight and reverse diabetes or prediabetes. In
addition, Nemaura combines an integrated app with proprietary
intellectual property and know-how, including more than 30 approved
or pending patents across multiple patent families, resulting in a
metabolic health program that stands apart from similar options
such as NOOM, etc.
The platform was designed to provide Nemaura with the
opportunity to diversify, using the exclusive offerings to expand
into both horizontal and vertical markets. The company has
announced the successful soft launch of its CE-approved medical
device in the United Kingdom and is reporting interest from
potential partners in Europe and Middle East; diabetes and obesity
are widespread in both of these regions. The UK licensee has
already ordered more than 200,000 sensors and forecasts a further 2
million for the next 2 years.
The NMRD system can also be adjusted to tackle the complete
metabolic health spectrum and other markets, including monitoring
body temperature, lactic acid levels, and alcohol and drug
ingestion. When partnered with predictive technologies such as
artificial intelligence and machine learning, the future for the
platform appears to be vast and diverse.
A New Take on Tradition
While continuous glucose monitoring (“CGM”) isn’t new, Nemaura
has a new take on the traditional treatment. The company has
developed a powerful system complete with mass-market sugarBEAT CGM
sensors, analytics, personalized coaching and a metabolic health
app. Particularly of note is the company’s innovative sensors. Most
sensors available today are invasive, requiring the insertion of a
one-centimeter-long filament in the arm, which must remain in place
for up to two weeks.
Nemaura’s proprietary sensors require no penetration of the
skin. The sensor is simply placed on the surface of the skin much
like a Band-Aid. In addition, Nemaura’s sensors do not need to be
worn for extended periods. In fact, those dealing with diabetes,
prediabetes or obesity typically only need to wear a sensor for a
few days each month. What’s more, the individual chooses the time
and day, simply disposing of the sensor after use. Fewer sensors
used for fewer days means lower costs of disease management.
Data transmission takes place in real time every five minutes,
with glucose profiles only needed at the end of each month to keep
in check. Patients using the WhyWait program receive guidance for
diet and exercise adjustments based on self-monitored blood glucose
(“SMBG”). The original weight-loss program was developed at the
Joslin Diabetes Centre, with more than 12 years of clinical
success; Nemaura’s BEATdiabetes program replicates the same
principles and ideas in a virtual platform shown to result in
durable weight loss without loss of muscle mass.
Changing the Benchmark
The benchmark for diabetes management for years has been HbA1C,
a measure of the amount of blood sugar attached to hemoglobin,
which is in red blood cells and carries oxygen from lungs
throughout the body. Unfortunately, non-CGM collected HbA1C levels
are only averages that can produce the same result while varying
significantly during any given period. It can be compared to a math
equation, with infinite ways to arrive at “7” (i.e., 5+2, 9-2,
11-4, 1+6, etc.).
One key benefit offered by Nemaura’s CGM-based system is the
ability to track the actual time that glucose levels are in a
normal range, called time in range (“TIR”). For HbA1C, this can be
defined as anywhere between 3.9 and 10.0 millimoles per liter
(mmol/l). Providing a way to record when and how much blood sugar
is outside that target range can be significant in disease
management. That information can provide understanding and the
ability to control TIR, which can lead to a reduction in diabetes
complications.
Capturing Attention, POs
With its innovative and power technology in place, Nemaura
expects to offer meaningful improvements in HbA1C, blood
cholesterol, blood pressure and sustainable weight loss — and
at an affordable price. Studies show that each case of diabetes
costs employers and insurers more than $9,000 on average every
year; that number is significantly greater than the $1,200 cost
reported for nondiabetic individuals.
The innovative tech and cost-saving numbers appear to be
capturing the attention of those in the industry looking for
solutions. A soft launch of NMRD’s BEAT diabetes platform in the
United Kingdom resulted in purchase orders for 200,000 sensors
along with rolling POs forecast for 2 million sensors in the next
two years. The platform has just been launched in the United States
as a wellbeing device called proBEAT, with a PMA filed with the FDA
as well. In addition, the company is reportedly in negotiations
with several third parties regarding its sugarBEAT and BEAT
platforms.
A Market Demanding Consideration
While diabetes and obesity may not top the list of most exciting
investment opportunities, the size of the market, totaling some 1.5
billion people currently and rising, certainly demands
consideration. Although the diseases have been traditionally
difficult to treat, technology is fueling a new optimism that
change is in the air.
WW
International Inc. (NASDAQ: WW), a human-centric
technology company powered by the world’s leading commercial
weight-management program, has teamed up
with Zoom Video Communications Inc. for the launch of
WW’s Wellness That Works(TM), a new app for Zoom that delivers an
embedded experience, seamlessly integrated within Zoom meetings.
This new in-product app is now available in the Zoom App
Marketplace. WW’s Wellness that Works app for Zoom encourages users
to adopt healthy habits from their virtual meetings — behind the
screen and beyond — no matter where they are.
Teladoc
Health Inc. (NYSE: TDOC), the first and only
comprehensive virtual care system, has partnered with DexCom Inc.
(NASDAQ: DXCM), the leader in real-time continuous
glucose monitoring (“CGM”), to offer joint Livongo for Diabetes and
Dexcom members CGM-powered insights, a new set of features and
reports that help members more easily visualize their health
information and understand how lifestyle decisions affect their
blood glucose levels. By combining Dexcom CGM data with additional
signals from Teladoc Health, including activity data and food
intake, CGM-powered insights offer members a complete health
profile and recommendations that support ongoing diabetes
management.
In addition, DexCom has received
clearance from the U.S. Food and Drug
Administration (“FDA”) for the Dexcom Partner Web APIs,
enabling invited third-party developers to integrate real-time CGM
data into their digital health apps and devices. “FDA clearance of
our real-time APIs further solidifies Dexcom as the
leader in interoperable CGM, giving Dexcom users even
more choice in how they view and interact with their glucose data,”
said Dexcom chief technology officer Jake Leach. “The new APIs
will help seamlessly integrate the power of real-time Dexcom CGM
data into some of the leading diabetes and digital health
solutions.” Several prominent diabetes and digital health companies
have been invited to access the real-time APIs and are already in
the testing and development phase.
DarioHealth
Corp. (NASDAQ: DRIO), a pioneer in the global digital
therapeutics market, announced a
new study at last month’s American Association of Diabetes
Care and Education Specialists annual conference demonstrating the
impact of Dario’s intelligent personalization platform. Dario’s
latest presentation examined the impact of personalized clinical
interventions delivered in real-time through the company’s digital
therapeutics platform. “Digital therapeutics can play a key role in
driving meaningful behavior change when the member experience is
truly tailored to follow each person’s unique journey. This
research is another example of how Dario is able to adapt and
respond to our members using a combination of real-time data and
clinically guided, highly personalized interventions to drive
healthier behaviors and deliver better results,”
said DarioHealth chief medical officer Omar Manejwala, MD.
Healthcare is at a crossroads, with a deep market demand for
both innovation and economic awareness. Companies that can meet
that demand and bring new solutions to the space are certain to
command attention.
For more information about Nemaura Medical Inc., please
visit Nemaura
Medical Inc. (NASDAQ: NMRD).
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and
content distribution company, one of 50+ brands within
the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to reach all target markets,
industries and demographics in the most effective manner
possible; (2) article and editorial
syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a
full array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024